Business Standard

Friday, December 20, 2024 | 03:15 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

Lupin hits 33-month low on weak Q4 results

It past two months, the stock underperformed the market by falling 24% against 3% rise in Sensex.

Lupin gets US FDA nod for antibacterial drug azithromycin suspension
Premium

SI Reporter Mumbai
Shares of Lupin dipped 7.7% to Rs 1,134, its lowest level since August 2014 on BSE in early morning trade, after the company’s quarterly net profit nearly halved to Rs 380 crore in March quarter (Q4FY17) from a year ago. The pharmaceutical company had reported net profit of Rs 748 crore in a year ago quarter.

Total revenue from operations during the reporting quarter grew marginally by 1% at Rs 4,253 crore against Rs 4,197 crore in the corresponding quarter of previous fiscal. Ebitda (earnings before interest, tax, depreciation and amortization) margin declined to 19.9% from 32.8%.

“Net

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in